Relacorilant for Ovarian Cancer: What Patients Need to Know About This Newly Approved Treatment

Relacorilant — now FDA-approved and sold under the brand name Lifyorli — is one of the most significant developments in ovarian cancer treatment in years. 

If you or someone you love is living with platinum-resistant ovarian cancer, this article breaks down what this drug is, how it works, and what the approval means in plain terms.

What Is Relacorilant?

Relacorilant is an oral medication that belongs to a new class of drugs called selective glucocorticoid receptor modulators (SGRMs). 

It’s the first of its kind to receive FDA approval for ovarian cancer. It’s taken by mouth, but the treatment regimen combines it with nab-paclitaxel (Abraxane), which is administered intravenously. 

You may also see it referred to as a selective glucocorticoid receptor antagonist (SGRA), the term used in both the ROSELLA trial and the FDA-approved label.

Early this year, the U.S. Food and Drug Administration approved relacorilant (Lifyorli) in combination with chemotherapy (nab-paclitaxel, also known as Abraxane) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with one to three prior lines of therapy, at least one of which included bevacizumab (Avastin). 

Adding to that significance, the April 2026 NCCN guidelines update now lists albumin-bound paclitaxel plus relacorilant as a preferred cytotoxic therapy for platinum-resistant disease in patients with up to three prior lines of therapy and prior bevacizumab: a designation that carries real weight when it comes to treatment access and insurance coverage.

This is a real, meaningful step forward. And for patients whose cancer has stopped responding to platinum-based treatment, it opens a door that wasn’t there before.

Why Does Platinum Resistance Matter?

To understand why relacorilant matters, it helps to understand the problem it’s solving.

Most patients are initially treated with platinum-based chemotherapy for ovarian cancer: drugs like carboplatin or cisplatin. For many, this works. But ovarian cancer is persistent. It comes back. And when it does, one of the most important factors guiding treatment decisions is timing: specifically, how long it has been since platinum-based chemotherapy ended.

If the cancer returns six months or more after platinum treatment, it’s considered platinum-sensitive. This means it’s likely to respond to platinum-based drugs again. Carboplatin may be used a second time, often combined with other chemotherapy agents.

But if the cancer returns within six months of completing platinum treatment, it’s classified as platinum-resistant. Different treatments are needed and yet the options are more limited.

There are a handful of agents used in platinum-resistant ovarian cancer, including pegylated liposomal doxorubicin (Doxil), topotecan, weekly paclitaxel, gemcitabine, and mirvetuximab soravtansine (Elahere), the latter being a newer targeted drug approved specifically for patients whose tumors express a protein called folate receptor alpha.

Each of these has its role, but none had previously demonstrated both a progression-free survival and overall survival benefit over standard weekly taxane chemotherapy in a Phase 3 trial, at least not until now, and with some important context to keep in mind. 

The progression-free survival improvement, while statistically significant, translated to roughly one month in absolute terms. The overall survival data, meanwhile, comes from an interim analysis and has not yet reached its final endpoint: meaning, the full picture is still emerging.

That’s the gap relacorilant was developed to fill, and the gap that the ROSELLA trial results have now addressed.

Learn more: “Chemotherapy Drugs for Ovarian Cancer: A Guide for Patients Before Starting Treatment”

How Does Relacorilant Work?

Here’s where things get genuinely interesting, because relacorilant doesn’t target the cancer directly the way traditional chemotherapy does. Instead, it targets the glucocorticoid receptor (GR): the cellular doorway through which cortisol exerts its effects. The drug doesn’t reduce cortisol levels or target cortisol itself; it works by blocking cortisol from activating that receptor in cancer cells. 

Cortisol is the hormone your body releases under stress. In ovarian cancer cells, GR activation is a known marker of poor prognosis. When cortisol activates these receptors, it triggers a chain of events that works against treatment on multiple fronts: it suppresses the cell’s natural death process (called apoptosis), which is exactly what chemotherapy is trying to trigger. It may also promote cellular adhesion, helping cancer cells grip more tightly to surrounding tissue and potentially evade immune detection. 

In short: cortisol can help cancer cells resist chemotherapy.

Relacorilant interferes with this process in a unique way. Rather than fully blocking the glucocorticoid receptor, it competitively binds to it, occupying the receptor and limiting cortisol’s ability to activate it, without shutting it down entirely. 

This selective modulation matters: by partially restraining GR activity instead of blocking it, relacorilant may avoid disrupting the HPA axis (the hormonal feedback system that regulates cortisol production), which is a known concern with drugs like mifepristone that can trigger adrenal insufficiency. The result (in theory) is reduced cortisol-driven resistance, allowing nab-paclitaxel to work more effectively.

One more thing worth noting: relacorilant works regardless of whether a tumor expresses specific biomarkers. Most targeted therapies require patients to test positive for a particular genetic marker to be eligible. Relacorilant doesn’t. This makes it a viable option for a much broader group of patients.

What Did the Clinical Trial Show?

The FDA approval is based on results from the ROSELLA Phase 3 trial, a global, randomized study conducted at 117 hospitals and cancer centers across 14 countries.

381 patients with platinum-resistant ovarian cancer were enrolled and randomly assigned to one of two groups:

• Combination group: relacorilant + nab-paclitaxel
• Control group: nab-paclitaxel alone

One detail worth noting: nab-paclitaxel was specifically chosen over standard paclitaxel because it doesn’t require corticosteroid premedication. Since corticosteroids activate the same glucocorticoid receptor that relacorilant is designed to modulate, using them together would work against the drug’s mechanism, making nab-paclitaxel the more compatible chemotherapy partner for this regimen.

The results were compelling on both primary endpoints the trial was designed to measure.

Progression-Free Survival

Patients receiving the relacorilant combination had a median progression-free survival (the time before the cancer grew or spread again) of 6.5 months, compared to 5.5 months in the control group. That’s a 30% reduction in the risk of disease progression or death (HR 0.70; p=0.0076). 

Overall Survival

The overall survival numbers are where this trial becomes personal. Patients receiving relacorilant lived a median of 16.0 months, more than four months longer than those on nab-paclitaxel alone (11.5 months). 

It’s worth noting that these figures come from an interim analysis and have not yet reached the trial’s final endpoint, so the complete survival picture is still unfolding. But for anyone who has watched a loved one fight recurrent ovarian cancer, even an early signal of that magnitude is anything but abstract.

Safety Profile

The side effect profile of the combination requires some nuance. 

On the surface, the type and nature of adverse events were broadly similar between both arms, but patients in the relacorilant combination group stayed on treatment about 30% longer, which matters when interpreting those numbers. 

When you account for that longer exposure, the rates of grade 3 or higher adverse events were actually higher in the combination arm. In other words, the drug didn’t add new or unexpected toxicities, but the overall side effect burden wasn’t identical either.

The most common side effects reported in at least 20% of patients included decreased hemoglobin (anemia), decreased neutrophils (neutropenia: a significant reduction in infection-fighting white blood cells that can become life-threatening and requires close monitoring), fatigue, nausea, diarrhea, decreased platelets (also called thrombocytopenia), rash, and decreased appetite. These are largely consistent with what’s already expected from nab-paclitaxel chemotherapy.  

What This Approval Means for Patients

For women navigating platinum-resistant ovarian cancer and their care teams, the approval of relacorilant is genuinely newsworthy.

It is the first treatment regimen to demonstrate both a progression-free survival and overall survival benefit compared to a weekly taxane — the most effective standard comparison available — in this patient population. And it does so without requiring biomarker selection, making it a potentially viable option for a broader group of patients than many targeted therapies.

It’s worth noting that relacorilant itself is taken orally at home. That said, the full regimen still requires IV nab-paclitaxel infusions on days 1, 8, and 15 of each cycle, so infusion center visits remain part of treatment. The oral component does reduce some of the daily treatment burden, but it doesn’t eliminate the need for regular clinic appointments.

If you have been told your cancer is platinum-resistant, ask your gynecologic oncologist whether relacorilant plus nab-paclitaxel may be an appropriate option for you.

Who Is Eligible?

Based on the FDA-approved label, relacorilant plus nab-paclitaxel is indicated for adults with:

• Epithelial ovarian, fallopian tube, or primary peritoneal cancer
• Platinum-resistant disease (progression within 6 months of platinum-based therapy)
• 1 to 3 prior lines of systemic treatment
• Prior treatment with bevacizumab (Avastin)

Patients who require corticosteroids for a life-sustaining reason are contraindicated and would not be eligible. Your oncologist will review your full medical history to determine if this treatment is right for your situation.

Relacorilant and the Bigger Picture of Ovarian Cancer Research

The approval of relacorilant for ovarian cancer is significant not just for what it is, but for what it represents: a new mechanism of action being applied to a disease that has long needed fresh approaches.

One important note for patients with low-grade serous ovarian cancer or borderline ovarian tumors: relacorilant is not indicated for these diagnoses. 

The ROSELLA trial enrolled patients with high-grade serous epithelial ovarian cancer specifically (and also included endometrioid and carcinosarcoma), and patients with LGSOC or borderline tumors were not included. 

This isn’t a gap in the research; it reflects the fact that these are biologically distinct diseases that require their own treatment approaches. If you’re navigating an LGSOC or borderline tumor diagnosis, the treatment landscape is also evolving in meaningful ways, including the recent FDA approval of avutometinib and defactinib for KRAS-mutated recurrent LGSOC, a separate but equally significant milestone worth knowing about.

Meanwhile, Corcept Therapeutics, the developer of relacorilant, is now studying the drug in additional cancer types — including endometrial, cervical, pancreatic, and prostate cancers — as well as in earlier stages of ovarian cancer. The hope is that blocking cortisol’s role in chemotherapy resistance could have broader implications across multiple tumor types.

For ovarian cancer patients monitoring research progress, these developments are worth watching. The science of ovarian cancer treatment is moving, and it’s moving in the right direction. Every approval, every clinical win, signals that the research community is listening, and that the investment in ovarian cancer science is paying off.

Navigating Your Options

Ovarian cancer treatment is complex, and decisions should always be made in close partnership with a specialist. If you haven’t already, connecting with a gynecologic oncologist, a doctor who specializes specifically in cancers of the reproductive system, can make a meaningful difference in the quality and accuracy of your care.

It’s also worth asking about ovarian cancer clinical trials. Relacorilant itself started as a clinical trial. The next treatment breakthrough for your specific diagnosis may already be in a study accepting patients. Remember: you don’t have to navigate this alone. And you deserve access to every option available.